Status message

Active context: kki_bg_colors_yellow

Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety and Pharmacokinetics of Denosumab in Children with Osteogenesis Imperfecta

Principal Investigator:

This is a prospective, multicenter single-arm study in children 2 to 17 years of age with osteogenesis imperfecta (OI). Approximately 150 subjects will be enrolled at 40 institutions including at least 30 subjects less than 7 years of age, and 5 at the KKI. All subjects will receive denosumab 1 mg/kg (up to a maximun of 60 mg) given subcutaneously every 6 months for 36 months. Enrollment is gated by age: 11-17 years as the first cohort, and 7-10 years as second cohort and the 2-6 year cohort therafter.

The primary endpoint is a change in baseline lumbar spine BMD Z-score as assessed by DXA over first 12 months. The secondary endpoints include lumbar and proximal femur DXA at 6, 18, 24 and 36 months, and occurrence of vertebral and non-vertebral fractures. Patient satisfaction parameters are also measured.

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.